Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125556221 | 12555622 | 1 | I | 20160617 | 20160701 | 20160714 | 20160714 | EXP | IT-MINISAL02-365691 | IT-TEVA-674582ACC | TEVA | 90.45 | YR | M | Y | 0.00000 | 20160714 | MD | IT | IT |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125556221 | 12555622 | 1 | PS | ENALAPRIL | ENALAPRIL | 1 | Oral | 20 MILLIGRAM DAILY; | 75479 | 20 | MG | ||||||||
| 125556221 | 12555622 | 2 | I | LUVION - 50 MG COMPRESSE - THERABEL GIENNE PHARMA S.P.A | CANRENONE | 1 | Oral | 50 MILLIGRAM DAILY; | 0 | 50 | MG | TABLET | |||||||
| 125556221 | 12555622 | 3 | C | ACARPHAGE - 50 MG COMPRESSE | 2 | Oral | 50 MG | U | 0 | 50 | MG | TABLET | |||||||
| 125556221 | 12555622 | 4 | C | LASIX | FUROSEMIDE | 1 | Oral | 50 MG | U | 0 | 50 | MG | TABLET | ||||||
| 125556221 | 12555622 | 5 | C | AVODART - 0.5 MG CAPSULE MOLLI | 2 | Oral | 1 DF | U | 0 | 1 | DF | CAPSULE | |||||||
| 125556221 | 12555622 | 6 | C | TRITTICO -75 MG COMPRESSE A RILASCIO PROLUNGATO | 2 | Oral | 75 MG | U | 0 | 75 | MG | PROLONGED-RELEASE TABLET | |||||||
| 125556221 | 12555622 | 7 | C | OMNIC - 0.4 MG CAPSULE RIGIDE A RILASCIO MODIFICATO | 2 | Oral | 1 DF | U | 0 | 1 | DF | CAPSULE | |||||||
| 125556221 | 12555622 | 8 | C | CLOPIDOGREL | CLOPIDOGREL BISULFATE | 1 | Oral | 75 MG | U | 0 | 75 | MG | |||||||
| 125556221 | 12555622 | 9 | C | BISOPROLOL HEMIFUMARATE | BISOPROLOL FUMARATE | 1 | Oral | 1.25 MG | U | 0 | 1.25 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125556221 | 12555622 | 1 | Hypertension |
| 125556221 | 12555622 | 2 | Hypertension |
| 125556221 | 12555622 | 3 | Diabetes mellitus |
| 125556221 | 12555622 | 4 | Cardiac failure |
| 125556221 | 12555622 | 5 | Benign prostatic hyperplasia |
| 125556221 | 12555622 | 6 | Depression |
| 125556221 | 12555622 | 7 | Benign prostatic hyperplasia |
| 125556221 | 12555622 | 8 | Product used for unknown indication |
| 125556221 | 12555622 | 9 | Cardiac failure |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125556221 | 12555622 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125556221 | 12555622 | Drug interaction | |
| 125556221 | 12555622 | Hyperkalaemia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125556221 | 12555622 | 1 | 20150219 | 20160617 | 0 | |
| 125556221 | 12555622 | 2 | 20151205 | 20160617 | 0 | |
| 125556221 | 12555622 | 3 | 20150219 | 20160617 | 0 | |
| 125556221 | 12555622 | 4 | 20150219 | 0 | ||
| 125556221 | 12555622 | 6 | 20150219 | 0 | ||
| 125556221 | 12555622 | 7 | 20150219 | 0 | ||
| 125556221 | 12555622 | 8 | 20150219 | 20160617 | 0 | |
| 125556221 | 12555622 | 9 | 20151205 | 20160617 | 0 |